Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944901 | 0.87 | IDO1 (0.56) | APPMRGPRX4MAOBNR4A2 | |
| SCHEMBL4697694 | 0.85 | MRGPRX4 (0.53) | APPMRGPRX4MAOB | |
| SCHEMBL21944597 | 0.81 | FFAR1 (0.39) | MRGPRX4MAOB | |
| SCHEMBL18002684 | 0.80 | MAOA (0.64) | MRGPRX4MAOBMAPTPOLB | |
| SCHEMBL4700356 | 0.80 | NR4A2 (0.68) | APPMRGPRX4MAOBNR4A2MAPT | |
| SCHEMBL15613736 | 0.77 | MAOB (0.58) | APPMAOBF2 | |
| SCHEMBL27735405 | 0.77 | APP (0.77) | APPMAOBF2MAPTL3MBTL1 | |
| SCHEMBL22964303 | 0.76 | APP (0.70) | APPMAOBNR4A2MAPTL3MBTL1 | |
| SCHEMBL14619058 | 0.75 | MAOB (0.51) | APPMRGPRX4MAOBNR4A2MAPT | |
| SCHEMBL4719177 | 0.75 | APP (0.50) | APPMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | APP 2183/4885MRGPRX4 4062/4885MAOB 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.